Urothelial and Colorectal Cancer - FOI Response Register

FoI Number
2023-221
Subject
Urothelial and Colorectal Cancer
Date Received
12/07/2023
Request and Response
  1. In the past 3 months, how many patients have been treated for urothelial cancer with the following agents?
  • Avelumab
  • Atezolizumab
  • Carboplatin with Gemcitabine
  • Carboplatin single or in any other combination
  • Cisplatin with Gemcitabine

1 patient. Shared treatment as Cisplatin not delivered in Shetland, Gemcitabine agent given

  • Cisplatin single or in any other combination
  • Nivolumab
  • Pembrolizumab
  • Any other systemic anti-cancer therapy
  • Palliative care only
  1. Does your trust participate in any ongoing clinical trials for the treatment of urothelial cancer? If so, can you please provide the name of each trial along with the number of patients taking part?

N/A

  1. In the past 3 months, how many patients have been treated for colorectal cancer [CRC] with the following agents?
  • Aflibercept
  • Bevacizumab
  • Capecitabine
  • CAPIRI
  • CAPOX (XELOX)

2 Patients

  • Cetuximab in combination with FOLFIRI/FOLFOX
  • Cetuximab not in combination with FOLFIRI or FOLFOX
  • Irinotecan only
  • FOLFIRI

 1 palliative

  • FOLFOX
  • Fluorouracil (5FU) only
  • Oxaliplatin only
  • Nivolumab
  • Panitumumab in combination with FOLFIRI/FOLFOX

1 palliative

  • Panitumumab not in combination with FOLFIRI or FOLFOX
  • Pembrolizumab
  • Raltitrexed
  • Ramucirumab
  • Regorafenib
  • Tegafur + Uracil
  • Any other systemic anti-cancer therapy
  • Palliative care only